Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo

Cancer Research

Volumn 63, Issue 10, 2003, Pages 2499-2505

  Giussani, Carlo ^a   Carrabba, Giorgio ^a   Pluderi, Mauro ^a   Lucini, Valeria ^a   Pannacci, Marilou ^a   Caronzolo, Dario ^a   Costa, Francesco ^a   Minotti, Matteo ^a   Tomei, Giustino ^a   Villani, Roberto ^a   Bikfalvi, Andreas ^b   Bello, Lorenzo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; HEMOPEXIN; THROMBOCYTE FACTOR 4;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RECURRENCE; CAPILLARY ENDOTHELIUM; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GLIOMA; HISTOCHEMISTRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; OSMOTIC MINIPUMP; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

AMINO ACID SEQUENCE; ANIMALS; BRAIN NEOPLASMS; CATTLE; CELL DIVISION; GLIOBLASTOMA; HEMOPEXIN; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSION PUMPS, IMPLANTABLE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM RECURRENCE, LOCAL; PEPTIDE FRAGMENTS; PLATELET FACTOR 4; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0038519967     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Carmeliet, P., and Jain, R. K. Angiogenesis in cancer and other diseases. Nature (Lond.), 407: 249-257, 2000.
2. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1997.
3. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1997.
4. Cao, Y. Endogenous angiogenesis inhibitors and their therapeutical implications. Int. J. Biochem. Cell Biol., 33: 357-369, 2001.
5. Kisker, O., Onizuka, S., Banyard, J., Komiyama, T., Becker, C. M., Achilles, E. G., Barnes, C. M., O'reilly, M. S., Folkman, J., and Pirie-Shepherd, S. R. Generation of multiple angiogenesis inhibitor by human pancreatic cancer. Cancer Res., 61: 7298-7304, 2001.
6. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
7. Hagedorn, M., and Bikfalvi, A. Target molecules for anti-angiogenic therapy: from basic research to clinical trials. Crit. Rev. Oncol. Hematol., 34: 89-110, 2000.
8. Kirsch, M., Strasser, J., Allende, R., Bello, L., Zhang, J., and Black, P. M. Angiostatin suppresses malignat glioma growth in vivo. Cancer Res., 58: 4654-4659, 1998.
9. Nguyen, J. T., Wu, P., Clouse, M. E., Hlatky, L., and Terwillinger, E. F. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res., 58: 5673-5677, 1998.
10. Tanaka, T., Manome, Y., Wen, P., Kufe, D. W., and Fine, H. A. Viral vector-meduated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat. Med., 3: 437-442, 1997.
11. Joki, T., Machluf, M., Atala, A., Zhu, J., Seyfried, N. T., Dunn, I. F., Abe, T., Carroll, R. S., and Black, P. M. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat. Biotechnol., 19: 35-39, 2001.
12. Kisker, O., Becker, C. M., Prox, D., Fannon, M., D'Amato, R., Flynn, E., Fogler, W. E., Sim, B. K., Allred, E. N., Pirie-Shepherd, S. R., and Folkman, J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res., 61: 7669-7674, 2001.
13. Sipos, E., and Brem, H. Local anti-angiogenic brain tumor therapies. J. Neurooncol., 50: 181-188, 2000.
14. Boiardi, A., Eoli, M., Salmaggi, A., Zappacosta, B., Fariselli, L., Milanesi, L. Broggi, G., and Silvani, A. Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumors. J. Neurooncol., 54: 39-47, 2001.
15. Walter, K. A., Tamargo, R. J., Olivi, A., Burger, P. C., and Brem, H. Intratumoral chemotherapy. Neurosurgery (Baltimore), 37: 1128-1245, 1995.
16. Read, T. A., Sorensen, D. R., Mahesparan, R., Enger, P. O., Timpl, R., Olsen, B. R., Hjelsteuen, M. H., Haraldseth, O., and Bjerkvig, R. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat. Biotechnol., 19: 29-34, 2001.
17. Olivi, A., DiMeco, F., Bohan, E., and Brem, H. Developing new methods for the treatment of malignant brain tumors: local delivery of anti-neoplastic agants using biodegradable polymers. Forum (Genova), 10: 152-165, 2000.
18. Bello, L., Lucini, V., Carrabba, G., Giussani, C., Machluf, M., Pluderi, M., Nikas, D., Zhang, J. P., Tomei, G., Villani, R., Carroll, R. S., Bikfalvi, A., and Black, P. M. Simultaneous inhibition of glioma angiogenesis, cell proliferation and migration by a naturally occurring fragment of human MMP-2. Cancer Res., 61: 8370-8376, 2001.
19. Bello, L., Carrabba, G., Giussani, C., Lucini, V., Cerutti, F., Scaglione, F., Landre', J., Tomei, G., Villani, R., Carroll, R. S., Black, P. M., and Bikfalvi, A. Low dose chemotherapy combined with an anti angiogenic drug reduces human glioma growth in vivo. Cancer Res., 61: 7501-7506, 2001.
20. Bello, L., Giussani, C., Carrabba, G., Pluderi, M., Lucini, V., Pannacci, M., Tomei, G., Villani, R., Scaglione, F., Carroll, R. S., and Bikfalvi, A. Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors. Clin. Cancer Res., 8: 3539-3548, 2002.
21. Joaun, V., Canron, X., Alemany, M., Caen, J. P., Quentin, G., Plouet, J., and Bikfalvi, A. Inhibition of angiogenesis of platelet factor-4 derived peptides and mechanism of action. Blood, 94: 984-993, 1999.
22. Hagedorn M., Zilberberg, L., Lozano, R. M., Cuevas, P., Canron, X., Redondo-Horcajo, M., Gimenez-Gallego, G., and Bikfalvi, A. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J., 15: 550-552, 2001.
23. Shoicet, M. S. Cell delivery to the CNS. Ag. Drug. Deliv. Rev., 42: 81-102, 2000.
24. Groothus, D. R. The blood brain barrier: a review of strategies for increasing drug delivery. J. Neuro-Oncol., 2: 45-59, 2000.
25. Crivellari, D., Magri, M. D., Buonadonna, A., Lombardi, D., Paolello, C., De Cicco, M., Fantin, D., and Veronesi, A. Continuous infusion fluoracil in the management od advanced breast cancer: a phase II study. Tumori, 86: 42-45, 2000.
26. Negro, S., Azuara, M. L., Sanchez, Y., Reyes, R., and Barcia, E. Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer, 10: 65-70, 2002.
27. Brooks, P. C., Silletti, S., von Schalcha, T. L., Friedlander, M., and Cheresh, D. A. Disruption of angiogenesis by PEX, a non catalytic metalloproteinase fragment with integrin binding activity. Cell, 92: 391-400, 1998.
28. Peifer, A., Kessler, T., Silletti, S., Cheresh, D. A., and Verna, I. M. Suppression of angiogenesis by lentiviral delivery of PEX, a non catalytic fragment of matrix metalloproteinases 2. Proc. Natl. Acad. Sci. USA, 97: 12222-12232, 2000.
29. Bobo, R., H., Laske, D., W., Akbasak, A., Morrison, P. L., Dedrick, R., L., and Oldfield, E. H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA, 91: 2076-2080, 1994.